Stepped Care Plus Cash Incentives Cuts 3‑Year Diabetes Incidence in Multiethnic Asian Prediabetes Cohort
Posted inAI Diabetes & Endocrinology news

Stepped Care Plus Cash Incentives Cuts 3‑Year Diabetes Incidence in Multiethnic Asian Prediabetes Cohort

The Pre-DICTED randomized trial found a stepped-care diabetes prevention program augmented with financial incentives reduced 3‑year diabetes conversion (34.8% vs 47.3%; adjusted RR 0.74), with metformin added for persistent high-risk participants and modest increased adverse events largely from GI symptoms.
AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news

AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights

AI-driven analysis identifies muscle volume as a robust predictor of survival in NSCLC, highlights metformin-modulated adipose effects, and elucidates molecular links to the obesity paradox, informing personalized prognosis beyond BMI.
SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts
Posted inDiabetes & Endocrinology Gastroenterology news

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑intermediate baseline fibrosis.
Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoints are needed to establish meaningful benefit.
Preoperative HbA1c Identifies Hidden Risk: Dysglycemia Predicts Worse 30‑Day Outcomes After General Surgery
Posted inDiabetes & Endocrinology General Surgery news

Preoperative HbA1c Identifies Hidden Risk: Dysglycemia Predicts Worse 30‑Day Outcomes After General Surgery

A large multicenter cohort shows that both diagnosed and previously unrecognized diabetes (by HbA1c) are common in general surgery patients and independently linked to higher 30‑day complications, readmissions, and mortality—supporting routine preoperative HbA1c assessment and individualized perioperative glycemic strategies.
Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings
Posted inCardiology Diabetes & Endocrinology news

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

A retrospective MIMIC‑IV cohort presented at AHA 2025 found perioperative metformin exposure in T2DM patients undergoing cardiac surgery associated with markedly lower 30‑, 90‑ and 360‑day mortality. Results are compelling but observational—randomized trials are needed to confirm causality and define perioperative use.
Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS
Posted inDiabetes & Endocrinology news

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promising but require randomized, biomarker‑driven studies to define metabolic and reproductive benefits and safety in this population.
Heat and Dehydration Increase Carbohydrate Use During Endurance Exercise — Heat Is the Dominant Driver
Posted inDiabetes & Endocrinology Emergency Medicine news

Heat and Dehydration Increase Carbohydrate Use During Endurance Exercise — Heat Is the Dominant Driver

A 2025 systematic review and meta-analysis found that endurance exercise in the heat increases carbohydrate oxidation and muscle glycogen use; dehydration amplifies this effect principally when combined with heat. Findings inform fueling and hydration strategies for athletes and at-risk populations.
Indole-3-Propionic Acid Bridges Gut Dysfunction and Diabetic Retinopathy — A Biomarker and Therapeutic Avenue
Posted inDiabetes & Endocrinology news Ophthalmology Pathology & Lab Medicine

Indole-3-Propionic Acid Bridges Gut Dysfunction and Diabetic Retinopathy — A Biomarker and Therapeutic Avenue

A Gut 2025 study identifies microbially produced indole-3-propionic acid (IPA) as a protective metabolite linking restored intestinal tryptophan handling to prevention of diabetic retinopathy in mice and associates low serum IPA with retinopathy in people with type 2 diabetes.
Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety
Posted inDiabetes & Endocrinology Nephrology news

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type 2 diabetes trials and a manageable hyperkalemia signal.
Less Sitting, More Sleep and MVPA Linked to Better Glycaemic Stability in Children with Type 1 Diabetes: A 2‑Year Compositional Analysis
Posted inDiabetes & Endocrinology news Pediatrics

Less Sitting, More Sleep and MVPA Linked to Better Glycaemic Stability in Children with Type 1 Diabetes: A 2‑Year Compositional Analysis

A longitudinal compositional analysis of 83 children with type 1 diabetes found that reallocating daily time away from sedentary behaviour toward sleep or moderate‑to‑vigorous physical activity (MVPA) was associated with lower HbA1c and interstitial glucose over two years.